Tag: BTG

SIRT better tolerated than sorafenib, but does not increase overall survival...

Selective internal radiation therapy (SIRT) also resulted in tumour response rates of 19% vs. 11.6% in the sorafenib group. Results of the SARAH trial demonstrate...

BTG receives CE mark for DC Bead Lumi

BTG has received Class III CE mark certification for DC Bead Lumi, the first commercially available radiopaque drug-eluting bead (DEB) in the EU which...

Adding interventional oncology to immuno-oncology

Some research data suggest there could be a synergistic effect between immunotherapy and minimally invasive procedures. Tumour types that do not respond to checkpoint...

BTG and SIO to explore role of minimally invasive therapies in...

BTG has announced a collaboration with the Society of Interventional Oncology (SIO; a global organisation working to nurture and support interventional oncology worldwide) to...

BTG’s Varithena launched in Canada

Following Health Canada regulatory approval, BTG is to launch its polidocanol injectable foam (Varithena), a drug/device combination product used to treat varicose veins, in...

First pulmonary embolism patients in Hong Kong treated with the BTG’s...

The first Hong Kong-based patients diagnosed with pulmonary embolism have been treated using the newly available BTG EKOS system. The EKOS system includes an...

BTG and Mirada Medical announce CE mark certification for Simplicit90Y dosimetry...

BTG and Mirada Medical announced CE mark certification for the Simplicit90Y dosimetry software, designed to optimise the planning of Y-90 selective internal radiation therapy...

BTG launches βETA radiation safety programme at CIRSE 2016

BTG has launched the βETA Radiation Safety Programme, a new initiative designed to reduce the risk of radiation exposure when performing selective internal radiation...